<DOC>
	<DOC>NCT00394173</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Inclusion criteria: Women of 18 65 years of age with IBSD as defined by the Rome II criteria. The Rome II criteria is a system used for diagnosing functional gastrointestinal disorders such as irritable bowel syndrome. It involves completing of a questionnaire about gastrointestinal symptoms. Patients who are 50 years of age and older must have had a colonoscopy OR a flexible sigmoidoscopy plus a doublecontrast barium enema within the past 5 years, which demonstrated no clinically significant findings. Clinically significant findings may include but are not limited to malignant tumors, multiple (≥3) or advanced adenomas, inflammatory bowel disease, diverticulitis, ischaemic colitis, lymphocytic colitis, or collagenous colitis. Patients must report ≥ 3 days with IBSrelated abdominal pain/discomfort plus at least 3 days of 2 or more of the following events during the baseline period: ≥ 3 bowel movements/day Bowel urgency Loose or watery stool Patients who answer "yes" to either or both of the two weekly satisfaction questions during the baseline period. The questions are: (1) Over the past week did you have satisfactory relief of your IBSrelated abdominal pain/discomfort? (2) Over the last week did you have satisfactory relief of your overall IBSD symptoms? Patients with hard or lumpy stools for more than one day during the baseline period. Lactose intolerant patients relieved on a lactose free diet. Use of antidepressants (tricyclic, SSRI etc), opioid analgesic drugs or drugs specifically affecting bowel motility during the course of the trial. Women of childbearing potential who do not use an acceptable methods of contraception. Pregnant or nursing (lactating) women. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>IBS</keyword>
	<keyword>diarrhea</keyword>
	<keyword>gastrointestinal functional disorder</keyword>
	<keyword>IBS-D</keyword>
</DOC>